Balyasny Asset Management
NKGNW

Balyasny Asset Management’s NKGen Biotech, Inc. Warrants NKGNW Stock Holding History

Balyasny Asset Management’s Portfolio NKGNW Stock Details NKGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-139,893
Closed -$14K – 3402
2024
Q4 		$14K Hold
139,893
– – ﹤0.01% 2661
2024
Q3 		$9.89K Hold
139,893
– – ﹤0.01% 2670
2024
Q2 		$13.8K Hold
139,893
– – ﹤0.01% 2485
2024
Q1 		$22.4K Hold
139,893
– – ﹤0.01% 2538
2023
Q4 		$9.89K Hold
139,893
– – ﹤0.01% 2421
2023
Q3 		$55.2K Sell
139,893
-107
-0.1% -$41 ﹤0.01% 2155
2023
Q2 		$31.9K Hold
140,000
– – ﹤0.01% 2145
2023
Q1 		$19.6K Hold
140,000
– – ﹤0.01% 2447
2022
Q4 		$11.9K Buy
140,000
+60,000
+75% +$5.04K ﹤0.01% 2540
2022
Q3 		$12K Hold
80,000
– – ﹤0.01% 2632
2022
Q2 		$21K Hold
80,000
– – ﹤0.01% 2477
2022
Q1 		$49K Hold
80,000
– – ﹤0.01% 2231
2021
Q4 		$92K Hold
80,000
– – ﹤0.01% 1973
2021
Q3 		$93K Buy
+80,000
New +$99.9K ﹤0.01% 1712

Other funds holding NKGNW

RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return

Balyasny Asset Management's NKGNW Position: Q1 2025 in Review

Balyasny Asset Management sold out of NKGen Biotech, Inc. Warrants (NKGNW) in Q1 2025, closing a stake of 139,893 shares — an estimated $14K sold.

Balyasny Asset Management first reported a position in NKGNW in Q3 2021 and held it in 14 quarters. The position peaked at $93K in Q3 2021. 3 funds tracked by Wall St. Rank hold NKGNW as of Q1 2025.

  • Balyasny Asset Management reported no remaining NKGen Biotech, Inc. Warrants position as of Q1 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 139,893 NKGen Biotech, Inc. Warrants shares in Q1 2025, an estimated $14K.
  • Balyasny Asset Management first reported a position in NKGen Biotech, Inc. Warrants in Q3 2021 and held it in 14 quarters.
  • Balyasny Asset Management's NKGen Biotech, Inc. Warrants position peaked at $93K in Q3 2021.
  • 3 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Warrants as of Q1 2025.

Based on Balyasny Asset Management's 13F filing for Q1 2025, filed 15 May 2025.